AAN Highlights

flipper_slider

Editor's Choice

We met with Dr Jeff Cummings, from the US Neurology Editorial Board, to discuss the current treatment landscape in Alzheimer’s disease, and recent clinical trials for new drugs. Speaker disclosures: In kind...

AAN Highlights Videos

Editor-in-Chief of US Neurology, Prof. Said Beydoun, reviews the differential diagnoses for multifocal motor neuropathy (MMN), and summarizes the emerging technologies for the diagnosis of MMN. Part 2 of 2 View part 1 here. Speaker disclosures: Consultant: Grifols, Shire. Speaker: Grifols....
Editor-in-Chief of US Neurology, Prof. Said Beydoun, reviews the differences between multifocal motor neuropathy (MMN) and entrapment neuropathy, and discusses the consequences of delayed MMN diagnosis. Part 1 of 2. View part 2 here. Speaker disclosures: Consultant: Grifols, Shire. Speaker:...
We catch up with Prof. Cris Constantinescu to discuss this year’s AAN coverage on multiple sclerosis, and he reveals which presentation he found the most interesting while here. Speaker disclosures: TBC Filmed at the American Academy of Neurology (AAN) Annual Meeting, Boston, US, April 2017
Dr Patrick Vermersch gives us his thoughts on tailoring multiple sclerosis treatment to the individual patient. Part 3 of 3. View part 1 here. View part 2 here. Speaker disclosures: Honoraria, consulting fees and research support from Roche, Biogen, Sanofi, Novartis, Servier, Merck, Alimera...
Dr Patrick Vermersch discusses the use of teriflunomide in multiple sclerosis and its effect on brain volume. Part 2 of 3. View part 1 here. View part 3 here. Speaker disclosures: Honoraria, consulting fees and research support from Roche, Biogen, Sanofi, Novartis, Servier, Merck, Alimera...
Dr Patrick Vermersch discusses the use of targeting B cells in multiple sclerosis. Part 1 of 3. View part 2 here. View part 3 here. Speaker disclosures: Honoraria, consulting fees and research support from Roche, Biogen, Sanofi, Novartis, Servier, Merck, Alimera Sciences and Teva. Filmed...
Prof. Martin Farlow, esteemed member of the US Neurology Editorial Board, discusses the use of antipsychotics in adults with dementia, and the benefit of tau imaging in the diagnosis of Alzheimers. Part 2 of 2. View part 1 here. Filmed at the American Academy of Neurology (AAN) Annual Meeting,...
Prof. Martin Farlow, esteemed member of the US Neurology Editorial Board, discusses the recent clinical trial of solanezumab in Alzheimer's disease and the current treatment landscape. Part 1 of 2. View part 2 here. Filmed at the American Academy of Neurology (AAN) Annual Meeting, Boston, US,...
Prof. Stuart Isaacson, Editorial Board member for US Neurology, catches up with us to talk about his recent study of apomorphine subcutaneous injection to combat delayed onset of morning levodopa dose, in patients with morning akinesia. He also briefly covers the benefits of using DaTscan in...
We met with Dr Jeff Cummings, from the US Neurology Editorial Board, to discuss the current treatment landscape in Alzheimer’s disease, and recent clinical trials for new drugs. Speaker disclosures: In kind research support from Avid Radiopharmaceuticals, Teva Pharmaceuticals, and CogState. Dr...
Prof. Dan Hanley summarizes the current treatment landscape and unmet needs in intraventricular hemorrhage, and discusses the findings of the CLEAR III trial. He also gives his insight into the commonly used methods to measure quality of life in survivors of hemorrhagic stroke. Speaker...
Prof. John Bodensteiner, from the US Neurology Editorial Board, discusses the diagnostic benefits of nerve biopsies in pediatric neurology and reviews the most exciting developments in spinal muscular atrophy and Duchenne muscular dystrophy. Speaker disclosures: Data Safety Review Board Biogen...